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Quantitative PCR (qPCR) for detection of fusion transcripts and
overexpressed genes is a promising tool for following minimal
residual disease (MRD) in patients with hematological malig-
nancies. Its widespread clinical use has to some extent been
hampered by differences in data analysis and presentation that
complicate multicenter clinical trials. To address these issues,
we designed a highly flexible MRD-reporting software program,
in which data from various qPCR platforms can be imported,
processed, and presented in a uniform manner to generate
intuitively understandable reports. The software was tested in a
two-step quality control (QC) study; the first step involved eight
centers, whose previous experience with the software ranged
from none to extensive. The participants received cDNA from
consecutive samples from a BCR-ABLþ chronic myeloid
leukemia (CML) patient and an acute myeloid leukemia (AML)
patient with both CBFb-MYH11 and WT1 target genes, they
conducted qPCR on their respective hardware platforms and
generated a series of reports with pre-defined features. In step
two, five centers used the software to report BCR-ABLþ MRD
in a harmonized manner, applying their recently obtained CML
international scale conversion factors. The QC study demon-
strated that this MRD-reporting software is suitable for efficient
handling of qPCR data, generation of MRD reports and
harmonization of MRD data.
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Introduction
The term minimal residual disease (MRD) denotes the miniscule
remnants of a cancer remaining after cytoreduction, which are
not recognizable by standard techniques. This relatively novel
concept has proven highly relevant in hematological malig-
nancies such as acute leukemias, where high complete
remission (CR) rates may be followed by relapses in more than
half of the patients.1
In this setting, quantitative RT-PCR (qPCR) has emerged as an
exciting tool, partly because of its extremely high dynamic range
(usually exceeding 5 logs), and partly because it is amenable to
detection of disease-specific alterations in these patients.
Leukemia-specific rearrangements, point mutations, gene dupli-
cations and overexpression of genes can be detected by qPCR,
in some instances with a sensitivity exceeding 1:100 000
leukemic cells.2 An added advantage of the qPCR method is
that it can be standardized, as evidenced, for example, by
multicenter efforts delineating the optimal control genes to
include in the assays, as well as the definition of universally
recognized protocols and primer designs.3–8
Although these features constitute great advantages for the
clinical integration of qPCR assays, major differences between
individual laboratories in terms of variation in the qPCR
procedures, together with differences in calculation of results
and presentation of MRD data both in daily routine and in
research, has hampered determination of the clinical use of
MRD assessment in multicenter settings and the development of
this technology to guide treatment approach. Given that this
variability is a crucial limitation to the dissemination of this
methodology, it was therefore decided under the auspices of the
European LeukemiaNet (ELN) Minimal Residual Disease Work
Package (WP12) to design a software package, which would
enable individual centers conducting qPCR for MRD measure-
ments to collect and express data in a standardized manner.
Accommodating local differences in qPCR hardware and MRD
calculation methods while retaining different options for
expressing and displaying data within the European network,
all presented major challenges that were surmounted in the
creation of a highly flexible and adaptable software package.
Here we describe the features of the MRD-reporting program
and its validation through an extensive quality control (QC)
study involving laboratories throughout Europe.
Materials and methods
MRD-reporting software
The software, which was developed in a close collaboration
between a steering committee established as part of the ELN
WP12 (MØ, CGN, DG and PH) and the IT company Langtved
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Data (Langtved Data Ltd, Ringsted, Denmark) was designed to
accommodate local handling and reporting of MRD data while
facilitating harmonization of MRD data irrespective of differ-
ences in qPCR platform, and with different standard options for
MRD and sensitivity calculation. As outlined in Figure 1, qPCR
data (sample IDs, target genes, Ct values and copy-number
information in case of absolute quantification) exported as a text
file from the qPCR equipment are imported to the database and
linked via the sample IDs to the corresponding patient. The
MRD levels can now be calculated and displayed by choosing
the report with the MRD formula and graphical layout of
interest. Finally, comments and conclusions can be added to
complete the report. A detailed description of the software
including the requirements in terms of hardware, operating
system and network structure is provided in Supplementary
MethodsFSoftware design.
Quality control study design
To validate the software and provide proof-of-principle for its
applicability in general use and in multicenter studies, we
designed a two-step QC study. The purpose of step one (QC I)
was to provide an overall validation of the package by software
installation and testing of basic functionalities, such as entering
patient- and sample-specific information into the database and
importing the corresponding qPCR data from the text file
generated from the qPCR run. Moreover, using different MRD
calculation and reporting features for the same data sets tested
the robustness of the MRD evaluation module. Test materials
comprised five consecutive peripheral blood (PB) samples from
a chronic myeloid leukemia (CML) patient (BCR-ABLþ ), five
consecutive PB samples from an acute myeloid leukemia (AML)
patient (CBFb-MYH11þ and overexpressing the WT1 gene), as
well as a K562 cell line sample. QC I included eight test
laboratories with different previous experience of using earlier
versions of the software, ranging from comprehensive
and/or extensive experience (laboratories E and F), to limited
(laboratories A, B and C) or no previous experience whatsoever
(laboratories D, G and H). The purpose of QC step two (QC II)
was to demonstrate the usefulness of the software for harmo-
nizing MRD data in multicenter studies. In CML, a recent
initiative within the European Treatment and Outcome Study
(EUTOS) was undertaken to establish an international scale for
comparison of molecular response rates between laboratories
and between clinical trials.9 Thereby, several laboratories have
obtained an international scale (IS) conversion factor (CF) that
allows for reporting of CML MRD data in a common scale,
independently of the local choice of sample processing and
qPCR methodology.9 Five of the laboratories participating in this
study had obtained an IS CF (C, D, F, G and H). In QC II, the five
CML PB samples used as test material were processed centrally
by laboratory F until storage in lysis buffer according to the
routine procedures in the five test laboratories. Further RNA
purification and qPCR procedures were carried out locally
according to the conditions underlying the IS CFs. The details of
the QC study may be found in Supplementary MethodsFQC
study design.
Software testing
In each laboratory, the software was installed as a single-PC
application. Successful creation in the database of patient files
with consecutive MRD samples, followed by platform-specific
import of qPCR data from text files, was a precondition for
further software testing and report generation. In QC I the
software was used to generate 16 specified reports covering
central software functions, including different choices of MRD
calculation method and graphic presentation modes, generation
of patient reports, as well as tabular lists of MRD data.
A thorough description of the reports can be found in
Supplementary MethodsFQC study design and Supplementary
Table 1. The reports were sent to laboratory F as read-only files
for centralized evaluation. Moreover, text files with primary data
from the qPCR hardware were included for elucidation of
aberrant results. Formulae for MRD and sensitivity calculation
together with criteria for defining a sample as MRD positive or
negative are provided in Supplementary Table 2. In QC II, four
reports were generated for analysis, showing an MRD graph or
results list before and after application of the CF in MRD
calculations, respectively.
As the participating laboratories were enrolled over a period
of time, they received the software at different time points.
Consequently, software glitches encountered in the first
laboratories were corrected before the software was sent to
the next laboratories. Given this, for the QC study there were
few minor differences between the software versions tested by
the participants. To verify the overall evaluation of the QC
study, and to be able to compare the MRD results while
eliminating possible differences due to lack of experience with
the software or incomplete adherence to the designations in the
QC protocol, all primary qPCR data generated in QC I were
reanalyzed in laboratory F using the latest version of the
software (version number 8.6, release 5, build 100).
Results
QC IFevaluation of software performance
QC I aimed at testing basic software functions such as
installation and entry of data into the database, as well as the
function of a number of central MRD-reporting features.
Different degrees of support were required from Langtved Data,
Figure 1 Software overview. (A) qPCR data are generated after
sample processing and qPCR reactions carried out according to local
procedures. (B) qPCR data are exported from the equipment as a text
file before entry into the MRD software. (C) Entry of patient- and
sample-specific data is followed by (D) import of the corresponding
qPCR data. The databrowser facilitates handling of the MRD-relevant
data by offering multiple standardized options in terms of MRD
calculation methods and display of MRD results. Thus, (E) after
selection of the relevant MRD calculation and display mode the results
may be evaluated and (F) a standardized MRD report to the clinician
may be generated (A full-size report may be seen in Supplementary
Figure 1).
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by telephone or online guidance, either during the installation
process or for metabase adjustment for successful import of data
to the database. These requirements were generally related to
local computer operating system settings. There was no need for
software support for further use of the program. All participants
successfully created patient files in the database. The 16
requested reports were returned by all participants except one
(Laboratory A), where six reports were missing because of failed
export of qPCR CML data from the qPCR equipment (Figure 2).
The reports revealed a few software glitches, some of which by
nature affected more than one report, as well as several
laboratories. These glitches were corrected during the course
of QC I, as revealed by the lack of software-related errors in
Laboratory H, which used the latest software version. A detailed
overview of the success rates of report generation according to
previous experience with the MRD-reporting software, together
with the composition of the 16 reports can be found in
Supplementary Table 1. Supplementary Figure 2 shows as an
example of software-generated MRD results a comparison
between the participating laboratories of the MRD graph from
report number 5, showing single-graph displays of the combined
CBFb-MYH11 and WT1 results in the studied AML patient. To
further compare the results between the laboratories, MRD
values were entered in Excel to superimpose the MRD curves for
relative and absolute quantification, respectively, for each of the
three target genes (Supplementary Figure 3). Most deviations
from the reference laboratory (F) thus revealed could after
examination of the text files with primary qPCR data be
explained by incorrect use of the software because of lack of
adherence to the QC study protocol and/or lack of experience
(described in the legend to Supplementary Figure 3). We
therefore conclude that although initially a certain degree of
support may be required primarily to ensure compatibility with
local computer settings, the corrected software is fully functional
and suited for flexible expression of MRD results.
QC IFconcordance of MRD results between
laboratories
The centralized reanalysis of the qPCR data with the latest
software version allowed us to evaluate the consistency of the
MRD results that could be generated from all of the eight
participating laboratories while consistently adhering to the
specifications of the QC I protocol (Figure 3). Generally, the
MRD results were highly concordant between the laboratories.
The overall range of sample-specific coefficients of variation
(CVs) among the eight laboratories was 21–201%, being
generally highest in samples with the lowest MRD level, which
is in accordance with a larger variability in the Ct values of
qPCR reactions with low target gene-copy numbers.10
QC IIFusage of CML IS CF in MRD software
A number of possibilities to adjust the MRD and sensitivity
calculation formulae have been included in the software. Such
adjustments, for example, allowance for differing PCR efficien-
cies may be made either at a general level, by introducing a
correction factor to the calculation formulae, or, at a sample-
specific level, by adding a correction factor on a single sample
in the application window. This feature was used in QC II for
adjustment of data with the CML CFs (Figure 4). Before CF
adjustment, laboratories C and F reported their MRD results as
K562-normalized relative values, normalizing to ABL, B2M and
GUS as control genes. Laboratories D and H reported absolute
values as BCR-ABL copies per 10 000 ABL copies, and
laboratory G reported absolute values as BCR-ABL per 100
GUS copies (Figure 4a). When comparing the results between
laboratories C and F, and between laboratories D and H, the
MRD results were highly concordant for each of these two
quantification methods. On application of the CFs the MRD
curves became more dispersed within these two groups,
however, the overall concordance between results seemed
good (sample-specific CV range: 51–99%) (Figure 4b). The
MRD-reporting software includes a formula for expression of
MRD data by the DDCt method11 (Supplementary Table 2).
When applying this calculation method on text file data from
laboratories C, D, F and H, using ABL as the control gene, the
sample-specific CV values were at a comparable level (range:
60–77%). However, the smaller mean MRD values by the DDCt
method compared with the results expressed at the IS positively
affect the size of the CV values, and when comparing sample-
specific variation using Levenes test for equality of variances
(STATA8, StataCorp LP, College Station, TX, USA) there was
better concordance between the laboratories when calculating
MRD results with the DDCt method than observed with the
CF-adjusted MRD results (Po0.0001) (Figure 4c). As this finding
is based on a restricted number of observations, a more general
conclusion on the optimal choice of calculation method for
MRD data harmonization would warrant a larger study.
Taken together, the flexible choice between different standard
MRD calculation options and the possibility to adjust MRD
results by a CF makes the MRD-reporting software highly useful
for harmonizing and comparing MRD data between centers.
Discussion
The translation of new technologies from the laboratory bench
to the clinical department requires not only formal validation of
the method, but, increasingly, also a communicative effort in
which data are presented in a meaningful way to the clinician
and, ultimately, to the patient. This is, in particular, relevant for
cancer patients, in whom disease eradication is far from certain.
For hematological malignancies, disease markers have been
identified over the course of the last 50 years since the
demonstration of the Philadelphia chromosome in CML.12
Given the existence of such markers, relapses are to an
increasing extent detectable in situations where the disease
Figure 2 Results of report generation in QC I. A–H refer to
laboratories A–H (see Supplementary Table 1 for a detailed listing).
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Figure 3 Overview of QC I MRD results generated after reanalysis with latest software version. MRD values from the tabular reports were entered
in Excel to superimpose the MRD curves for relative and absolute quantification, respectively, for each of the three target genes. y-axis units:
absolute quantification: MRD is expressed as BCR-ABL copies/10 000 ABL copies. Relative quantification: MRD is expressed relative to the level in
the diagnostic sample.
Figure 4 MRD harmonization in CML. The graphs were generated in Excel. (a) Data before application of the laboratory-specific CFs. Routinely
laboratories C and F reported relative MRD using K562 cell line equivalents, Laboratory D and H reported MRD as BCR-ABL copies per 10 000
ABL copies, and Laboratory G reported MRD as BCR-ABL copies per 100 GUS copies. The unit of the y-axis is laboratory-dependent as revealed by
the curve legends. (b) Data after application of the CFs. Common y-axis unit: IS %. (c) MRD data of laboratories C, D, F and H calculated by the
DDCt method using the ABL control gene, and using the diagnostic sample as calibrator sample.
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has not manifested itself clinically. This underlines the need for
a form of data presentation that is as lucid and unequivocal
as possible.
The software package presented here allows the user to
import MRD data from a variety of qPCR platforms. Following
this, a database can be created that contains the qPCR data tied
together with patient-specific information and necessary details
for the actual sample. The software offers a number of choices
for data processing in terms of MRD calculation method,
graphical display of the MRD values, and layout of the final
report to the requesting clinician. The flexibility thus included
may be largely expanded upon by the many options to edit
program elements that have been granted to the locally
appointed software administrator.
The software offers a number of obvious advantages for
routine qPCR and MRD applications in terms of data security
and storage, as well as streamlining of the work process. From a
time-economical point of view, this may be highly valuable,
not least for high-throughput laboratories. Moreover, the
possibility to easily save and display consecutive control sample
data is an important option in terms of quality measures in
the laboratory. Because of the built-in data security, the software
meets the requirements for prospective accreditation of the
MRD application.
We believe that this software may also be an important tool in
the context of consolidating the use of MRD assessments for
directing treatment of hematological malignancies. Although
many laboratories perform qPCR monitoring of MRD in
leukemic patients, the data generated have hitherto been mainly
descriptive. However, clinical trial initiatives, such as the UK
Medical Research Council AML15 study that elucidated
treatment of acute promyelocytic leukemia patients based on
qPCR detection of PML-RARA transcripts using an internation-
ally standardized method,13 have now been undertaken in order
to validate the implementation of MRD monitoring into clinical
decision making.
Our QC study served to provide proof-of-principle of the
applicability of the software, and to concomitantly test the
software before release within the ELN. To eliminate a major
part of the variation to be expected between different
laboratories conducting qPCR, identical cDNA samples were
used for testing in QC I. In this setting, we observed only a minor
qPCR procedure-based variation between the test laboratories.
However, when focusing on the clinical relevance of MRD, it
was even more important that we were able to demonstrate a
parallelism between the MRD curves, as this gives rise to a
restricted variation in the fold changes between consecutive
samples between the different test laboratories. This finding,
which to our knowledge has not previously been elaborated on
in a multicenter setting, may be of particular importance in
follow-up settings where prognostication after induction therapy
or determination of molecular relapse are based on a fold
change compared with the previous sample(s).14–16
Calculation formulae included in the software can be edited
by the user, allowing for adherence to the local standard of
expressing MRD results, including reporting the sensitivity
afforded by each sample. On the other hand, there is the
opportunity to add to the default formulae a correction factor for
individual samples, as well as on a general basis, which may be
highly relevant in case of assay standardization against a
common inter-laboratory reference. In QC II this software
feature was tested using a second series of CML samples that
were processed according to local procedures and therefore
were amenable to application of the CML IS CFs obtained in the
five participating laboratories. All laboratories successfully
generated reports expressing MRD data according to the CML
IS, thereby demonstrating the potential of the program to
facilitate the harmonization of multicenter-derived MRD data.
The software includes a formula for relative quantification of
MRD by the DDCt method.11 When we calculated MRD values
by this method in the four laboratories in QC II who used ABL as
the control gene, we found a very high degree of concordance of
the MRD results between the laboratories. This indicates that the
DDCt method may represent an alternative method for
harmonizing MRD data. Whether this should indeed be the
case in CML, as well as in other leukemias will await larger
multicenter studies.
As a starting point, we intended to interfere only minimally
during the testing process in the laboratories. We found that all
laboratories required some degree of support for configuring the
software according to local IT systems, whereas in terms of using
the software, no help was given. Not surprisingly, we observed a
higher success rate of the QC study for the laboratories that had
preceding comprehensive or extensive experience with the
software compared with the laboratories with no previous
experience. However, the requisites for successful use of the
software may be built rapidly for new users.
In conclusion, this software is an excellent tool to be used in
the daily routine laboratory for calculating and reporting MRD
data to clinical use, and an important step in harmonizing the
handling of MRD data arising from different qPCR platforms and
reporting of the results. This should be of value not only to users
at the single institution, but also in the collaborative group
setting, which is a prerequisite in these relatively rare cancers,
where multicenter studies can be conducted with decentralized
performance of MRD determinations.
Perspectives
This software package has been released to all members of the
European LeukemiaNet initiative and will be made available to
other users. The validation procedures outlined above should
make this package suitable for general use in translational
hematology allowing standardized reporting of MRD results
(eg, use of IS in CML trials), and facilitating comparison of results
obtained between trial groups. Indeed the software package is
now fully implemented for reporting of MRD data to direct
treatment approach in the UK National Cancer Research
Institute AML17 trial (http://aml17.cardiff.ac.uk/).
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